These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38846976)

  • 21. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
    Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
    BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck.
    Honoré N; van Marcke C; Galot R; Helaers R; Ambroise J; van Maanen A; Mendola A; Dahou H; Marbaix E; Van Eeckhout P; Longton E; Magremanne M; Schmitz S; Limaye N; Machiels JP
    Ann Oncol; 2023 Dec; 34(12):1175-1186. PubMed ID: 37879442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Next Generation Sequencing of Tumor and Matched Plasma Samples: Identification of Somatic Variants in ctDNA From Ovarian Cancer Patients.
    Barbosa A; Pinto P; Peixoto A; Guerra J; Pinheiro M; Santos C; Pinto C; Escudeiro C; Bartosch C; Santos R; Brandão A; Silva J; Teixeira MR
    Front Oncol; 2021; 11():754094. PubMed ID: 34660321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
    Gale D; Heider K; Ruiz-Valdepenas A; Hackinger S; Perry M; Marsico G; Rundell V; Wulff J; Sharma G; Knock H; Castedo J; Cooper W; Zhao H; Smith CG; Garg S; Anand S; Howarth K; Gilligan D; Harden SV; Rassl DM; Rintoul RC; Rosenfeld N
    Ann Oncol; 2022 May; 33(5):500-510. PubMed ID: 35306155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients.
    van Ginkel JH; Huibers MMH; van Es RJJ; de Bree R; Willems SM
    BMC Cancer; 2017 Jun; 17(1):428. PubMed ID: 28629339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutated
    Kampel L; Feldstein S; Tsuriel S; Hannes V; Carmel Neiderman NN; Horowitz G; Warshavsky A; Leider-Trejo L; Hershkovitz D; Muhanna N
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The diagnostic value and prospects of gene mutations in circulating tumor DNA for head and neck cancer monitoring.
    Yang X; Xu X; Zhang C; Ji T; Wan T; Liu W
    Oral Oncol; 2022 May; 128():105846. PubMed ID: 35358785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ctDNA as a biomarker of progression in oesophageal adenocarcinoma.
    Bonazzi VF; Aoude LG; Brosda S; Lonie JM; Patel K; Bradford JJ; Koufariotis LT; Wood S; Smithers BM; Waddell N; Barbour AP
    ESMO Open; 2022 Jun; 7(3):100452. PubMed ID: 35798469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The development of a liquid biopsy for head and neck cancers.
    Schmidt H; Kulasinghe A; Kenny L; Punyadeera C
    Oral Oncol; 2016 Oct; 61():8-11. PubMed ID: 27688098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.
    Weber ZT; Collier KA; Tallman D; Forman J; Shukla S; Asad S; Rhoades J; Freeman S; Parsons HA; Williams NO; Barroso-Sousa R; Stover EH; Mahdi H; Cibulskis C; Lennon NJ; Ha G; Adalsteinsson VA; Tolaney SM; Stover DG
    Genome Med; 2021 May; 13(1):89. PubMed ID: 34016182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liquid biopsy in head and neck squamous cell carcinoma: circulating tumor cells, circulating tumor DNA, and exosomes.
    Yang WY; Feng LF; Meng X; Chen R; Xu WH; Hou J; Xu T; Zhang L
    Expert Rev Mol Diagn; 2020 Dec; 20(12):1213-1227. PubMed ID: 33232189
    [No Abstract]   [Full Text] [Related]  

  • 32. Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients.
    Chan HT; Nagayama S; Otaki M; Chin YM; Fukunaga Y; Ueno M; Nakamura Y; Low SK
    Front Oncol; 2022; 12():1055968. PubMed ID: 36776372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA.
    Huebner A; Black JRM; Sarno F; Pazo R; Juez I; Medina L; Garcia-Carbonero R; Guillén C; Feliú J; Alonso C; Arenillas C; Moreno-Cárdenas AB; Verdaguer H; Macarulla T; Hidalgo M; McGranahan N; Toledo RA
    Genome Med; 2023 Apr; 15(1):27. PubMed ID: 37081523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell-Free DNA Kinetics in a Pre-Clinical Model of Head and Neck Cancer.
    Muhanna N; Di Grappa MA; Chan HHL; Khan T; Jin CS; Zheng Y; Irish JC; Bratman SV
    Sci Rep; 2017 Dec; 7(1):16723. PubMed ID: 29196748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma.
    Payne K; Spruce R; Beggs A; Sharma N; Kong A; Martin T; Parmar S; Praveen P; Nankivell P; Mehanna H
    Head Neck; 2018 Jul; 40(7):1598-1604. PubMed ID: 29542214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma.
    Wang X; Yu N; Cheng G; Zhang T; Wang J; Deng L; Li J; Zhao X; Xu Y; Yang P; Bai N; Li Y; Bi N
    Clin Transl Med; 2022 Nov; 12(11):e1116. PubMed ID: 36437506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multi-Site Tumour Sampling Improves the Detection of Intra-Tumour Heterogeneity in Oral and Oropharyngeal Squamous Cell Carcinoma.
    Jie W; Bai J; Yan J; Chi Y; Li BB
    Front Med (Lausanne); 2021; 8():670305. PubMed ID: 34041255
    [No Abstract]   [Full Text] [Related]  

  • 38. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing.
    Zhang Y; Chang L; Yang Y; Fang W; Guan Y; Wu A; Hong S; Zhou H; Chen G; Chen X; Zhao S; Zheng Q; Pan H; Zhang L; Long H; Yang H; Wang X; Wen Z; Wang J; Yang H; Xia X; Zhao Y; Hou X; Ma Y; Zhou T; Zhang Z; Zhan J; Huang Y; Zhao H; Zhou N; Yi X; Zhang L
    Mol Cancer; 2019 Jan; 18(1):7. PubMed ID: 30626401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression.
    Lau E; McCoy P; Reeves F; Chow K; Clarkson M; Kwan EM; Packwood K; Northen H; He M; Kingsbury Z; Mangiola S; Kerger M; Furrer MA; Crowe H; Costello AJ; McBride DJ; Ross MT; Pope B; Hovens CM; Corcoran NM
    Genome Med; 2020 Aug; 12(1):72. PubMed ID: 32807235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.